2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepine-5-carboxylic acid amide derivatives as gamma-secretase inhibitors for the treatment of Alzheimer's disease

Details for Australian Patent Application No. 2004238037 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Goodnow, Robert Alan Jr.; Galley, Guido; Peters, Jens-Uwe

Agent Spruson & Ferguson

Pub. Number AU-B-2004238037

PCT Pub. Number WO2004/100958

Priority 03011040.7 19.05.03 EP

Filing date 14 May 2004

Wipo publication date 25 November 2004

Acceptance publication date 26 November 2009

International Classifications

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C07D 267/14 (2006.01) Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

24 November 2005 PCT application entered the National Phase

  PCT publication WO2004/100958 Priority application(s): WO2004/100958

8 December 2005 Amendment Made

  The nature of the amendment is: Amend co-inventor from Peters, Jens Uwe to Peters, Jens-Uwe

26 November 2009 Application Accepted

  Published as AU-B-2004238037

25 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004238038-Bicalutamide forms, compositions, and processes thereof

2004238026-Medical implants comprising biocompatible coatings